UPDATE: Hedge Fund Manger Kyle Bass Wins Right to Challenge Four Patents on Acorda's (ACOR) Ampyra
- S&P 500, Dow set to rise as economic growth heats up
- Didi (DIDI) Gains on WSJ Report It Considers Going Private, Company Denies
- Facebook (FB) Tops Profit and Revenue Estimates, But Shares Lower on Warning of Significant Growth Slowdown, Analyst Still Raises PT to a New 'Street High'
- Robinhood (HOOD) Priced IPO at Lower End of Range as Some Investors Stayed on Sidelines Over Frothy Valuation
- Hang Seng Index Rebounds as China Moves to Reassure Investors It Will Allow US IPOs
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - March 11, 2016 3:00 PM EST)
Hedge fund manager Kyle Bass' Coalition for Affordable Drugs won the right to challenge Acorda Therapeutics (NASDAQ: ACOR) patents 8663685 and 8440703 on Ampyra, according to several reports reports, including Bloomberg. The Patent Trial and Appeals Board said the hedge fund manager has a reasonable likelihood of winning its argument.
Patents are set to expire in 2025.
Update: PTAB also agreed to review Ampyra patents 8354437 and 8007826.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Nikola (NKLA) Founder Trevor Milton Charged with Making False Statements - Bloomberg
- UPDATE: CryoLife (CRY) Sells PerClot to Baxter for $60.8M
- Ferroglobe (GSM) Announces ITC Confirms Malaysian Imports Have Injured U.S. Silicon Metal Industry; U.S. Industry Applauds Antidumping Order
Create E-mail Alert Related CategoriesCorporate News, Hedge Funds, Hot Corp. News, Litigation, Trader Talk
Related EntitiesHedge Funds
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!